SCHEDULE 13G/A: Bain Capital Life Sciences Maintains Significant Stake in Disc Medicine, Inc.
Beneficial Ownership Disclosure
Bain Capital Life Sciences Opportunities III, LP has disclosed a continued beneficial ownership of 3.3% in Disc Medicine, Inc. as of December 31, 2024.
Summary
- Bain Capital Life Sciences Opportunities III, LP, a Delaware limited partnership, filed an Amendment No. 3 to its Schedule 13G regarding its beneficial ownership in Disc Medicine, Inc.
- As of December 31, 2024, the Reporting Person beneficially owned 983,500 shares of Disc Medicine, Inc. Common Stock.
- This ownership represents approximately 3.3% of the outstanding shares of Common Stock.
- The percentage is based on 29,757,732 shares of Common Stock outstanding as of November 7, 2024, as reported by Disc Medicine, Inc. in its Quarterly Report on Form 10-Q.
- Bain Capital Life Sciences Opportunities III, LP holds shared voting and shared dispositive power over all 983,500 shares.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The document is a factual disclosure of beneficial ownership. The continued holding by a reputable life sciences investor like Bain Capital can be interpreted as a moderately positive signal of confidence in the company, hence a slightly positive score.
Positives
- The continued significant holding by Bain Capital Life Sciences, a prominent investment firm specializing in the life sciences sector, may signal ongoing confidence in Disc Medicine, Inc.'s long-term prospects.
- The disclosure indicates a stable institutional ownership base, which can be viewed favorably by other investors.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding Disc Medicine, Inc.'s future performance or strategic direction. It is solely a disclosure of beneficial ownership.
Industry Context
This filing reflects a routine disclosure of an institutional investor's stake in a publicly traded biotechnology company. Such disclosures are common in the life sciences sector, where specialized funds like Bain Capital Life Sciences frequently invest in emerging and established companies.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially reinforcing confidence due to Bain Capital's continued investment.
- Investors: Offers insight into the institutional ownership structure of Disc Medicine, Inc.
Key Dates
| Date | Description |
|---|---|
| 2024-11-07 | Date as of which Disc Medicine, Inc. reported 29,757,732 shares of Common Stock outstanding in its Quarterly Report on Form 10-Q. |
| 2024-12-31 | Date of event which requires the filing of this statement, reflecting the beneficial ownership position. |
| 2025-02-14 | Date the Schedule 13G Amendment No. 3 was signed and filed. |
Keywords
Disc Medicine, Bain Capital Life Sciences, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.